News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Cingulate Therapeutics
NEWS
JOBS
IN THE PRESS
NEWS
Drug Development
Clinical Catch-Up: 3’s the Charm for Pfizer-BioNTech Vaccine in Kids & More
A roundup of last week’s top clinical trial announcements and news, including updates from Pfizer, BioNTech, Ocugen and more.
May 27, 2022
·
10 min read
·
Mark Terry
Bio NC
Anxious? Activate Your Anterior Cingulate Cortex With a Little Meditation, Wake Forest University Baptist Medical Center Study
June 5, 2013
·
1 min read
JOBS
Currently, there are no jobs for this company on BioSpace
Browse all jobs
here
Oops!
There was an issue retrieving the jobs list. Please reload the page to view more jobs.
Title
Location
Company Name
Desc
View details
IN THE PRESS
Drug Development
Dr. Vince Clinical Research Announces First Dosing in Cingulate Therapeutics’ CTx-1301 Phase III Laboratory Classroom Study in ADHD Patients
September 6, 2023
·
3 min read
Drug Development
Cingulate Announces Presentation of Full Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD at Psych Congress 2023Data Accepted as Finalist for First Annual Poster Awards
September 5, 2023
·
8 min read
Business
Cingulate Inc. Reports Second Quarter 2023 Financial Results and Provides Clinical and Business Update
August 14, 2023
·
9 min read
Drug Development
Cingulate Announces Positive Top-Line Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHDResults Indicative that CTx-1301 Provides Entire Active-Day Efficacy with Optimal Onset and Duration
July 11, 2023
·
10 min read
Drug Development
Cingulate Successfully Manufactures Clinical Supply – Initiation of Pediatric Phase 3 Studies to Commence in July and August
June 29, 2023
·
6 min read
BioMidwest
Cingulate to Participate in the Healthcare Virtual Conference Part II Presented by Maxim Group and Hosted by M-Vest
June 14, 2023
·
2 min read
Drug Development
Cingulate Completes Phase 3 Adult Trial of CTx-1301 (dexmethylphenidate) for ADHD
June 8, 2023
·
9 min read
BioMidwest
Cingulate to Present at 13th Annual LD Micro Invitational
May 25, 2023
·
1 min read
BioMidwest
Cingulate, Indegene to Participate in Benzinga All Live Access Event
May 12, 2023
·
2 min read
Business
Cingulate Inc. Reports First Quarter 2023 Financial Results and Provides Clinical and Business Update
May 10, 2023
·
11 min read
